Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.

@article{Koonce2015CombinationOG,
  title={Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-$\alpha$ and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.},
  author={N. Koonce and C. Quick and M. Hardee and A. Jamshidi‐Parsian and J. Dent and G. Paciotti and D. Nedosekin and Ruud P M Dings and R. Griffin},
  journal={International journal of radiation oncology, biology, physics},
  year={2015},
  volume={93 3},
  pages={
          588-96
        }
}
PURPOSE Although remarkable preclinical antitumor effects have been shown for tumor necrosis factor-α (TNF) alone and combined with radiation, its clinical use has been hindered by systemic dose-limiting toxicities. We investigated the physiological and antitumor effects of radiation therapy combined with the novel nanomedicine CYT-6091, a 27-nm average-diameter polyethylene glycol-TNF-coated gold nanoparticle, which recently passed through phase 1 trials. METHODS AND MATERIALS The… Expand
Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors
TLDR
CYT-21625 is effective in mice with P NETs and metastatic human thyroid cancer with no toxicities and should be studied in patients with advanced PNETs and thyroid cancer. Expand
Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry.
TLDR
Overall, CTCs correlated with tumor progression and suggest CTC enumeration described herein may be useful in clinical management of solid tumor malignancies. Expand
Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.
TLDR
This review will analyze different TNFα-mediated tumor vessel-targeted therapies in both humans and tumor mouse models, with emphasis on the role played by the cross-talk between natural killer and dendritic cells and on the ability of TNF α to trigger tumor vessel activation and normalization. Expand
Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells
TLDR
This review summarizes the efficacy of metal-based NanoEnhancers against cancers in both in vitro and in vivo systems for a range of ionizing radiations including gamma-ray, X-rays, and charged particles. Expand
Local radiotherapy reduces circulating tumor cells and metastatic progression : Role of circulating cell detection in response to vascular damaging therapies
Noninvasive biological readouts of tumor metastatic risk and therapeutic efficacy are needed as healthcare costs rise. Conventional imaging modalities are expensive; require significant periods ofExpand
Cancer nanomedicines: Opportunities and challenges
TLDR
Cancer patients should be treated with CYT-6091 prior to chemotherapy in order to reduce tumor size in situ, potentially leading to less complicated followon surgery, less time in hospital, improved patient outcomes, and ultimately reduced healthcare cost associated with treating patients with cancer. Expand
Recent Advances in Cancer Therapy Based on Dual Mode Gold Nanoparticles
TLDR
The interaction mechanisms of AuNPs with cancer cells via the effects of non-ionizing and ionizing radiations are referred to and recent existing experimental data is provided as a baseline for the design of optimized protocols in PTT, RT and PTT/RT combined treatment. Expand
Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure
TLDR
The novel approach using gold nanoparticle carrying recombinant human tumor necrosis factor, a vascular disrupting agent, that preferentially and specifically targets tumors while the systemic toxicity is markedly reduced resulted in significantly reduced tumor burden and increased survival in multiple mouse models. Expand
Design of nanocarriers based on complex biological barriers in vivo for tumor therapy
Abstract Nanoscale drug delivery systems (NDDS) have shown great potential in tumor treatment due to its unique advantages, especially its unique enhanced permeability and retention effect (EPR) inExpand
Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer
TLDR
Preclinical and clinical studies have shown that these effects may partially be avoided via tumor-targeted delivery strategies and TNF-α alone or combined with chemotherapy and radiotherapy can function as an adjuvant in the treatment of breast cancer. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 35 REFERENCES
Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α
TLDR
Targeted delivery of low doses of NGR-TNF to the tumor vasculature can increase the efficacy of various drugs acting via different mechanisms, including doxorubicin and melphalan, cisplatin, paclitaxel, and gemcitabine. Expand
Enhancement of tumor thermal therapy using gold nanoparticle–assisted tumor necrosis factor-α delivery
TLDR
A newly developed nanoparticle delivery system consisting of 33-nm polyethylene glycol–coated colloidal gold nanoparticles (PT-cAu-TNF-α) with incorporated T NF-α payload (several hundred TNF- α molecules per nanoparticle) is used to maximize tumor damage and minimize systemic exposure to TNF -α. Expand
Anti‐tumor effects of tumor necrosis factor alone or combined with radiotherapy
TLDR
Recombinant human tumor necrosis factor was investigated for its ability to increase the response of murine tumors to ionizing radiation and its augmentation of tumor radioresponse and it is suggested that rHuTNF is potentially beneficial in combination with radiotherapy. Expand
Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.
TLDR
The potential of nanoparticle-conjugated VDAs to significantly improve cancer therapy is demonstrated by preconditioning tumor vasculature to a secondary insult in a targeted manner and NP-TNF was found to enhance thermal therapy in the absence of neutrophil recruitment. Expand
Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
TLDR
The maximal tolerated dose of tumor necrosis factor-alpha when given with radiotherapy is at least 150 microg/m2 and a dose-limiting toxicity was not observed and a maximum tolerated dose could not be defined. Expand
Nanotherapeutics for enhancing thermal therapy of cancer
  • R. Visaria, J. Bischof, +4 authors R. Griffin
  • Medicine
  • International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • 2007
TLDR
CYT-6091, by selectively delivering TNF to solid tumors, improves the safety of TNF treatment and augments cancer thermal therapy efficacy possibly by inducing a tumor-localized inflammatory response. Expand
Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
TLDR
Data suggest that the interaction between radiation inducible TNF-alpha and X-irradiation occurs selectively within the tumor vessels. Expand
Tumor Vasculature-Targeted Recombinant Mutated Human TNF-α Enhanced the Antitumor Activity of Doxorubicin by Increasing Tumor Vessel Permeability in Mouse Xenograft Models
TLDR
Targeted delivery of low doses of recombinant mutated human TNF-α specifically targeted to the tumor vasculature combined with the chemotherapeutic agent doxorubicin increases the antitumor efficacy of chemotherapy drugs. Expand
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor
TLDR
Direct evidence is provided that TNF and cAu‐TNF selectively and rapidly alter permeability in tumor neovasculature; a phenomenon that may be exploited to enhance selective delivery of chemotherapeutics to tumor. Expand
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
TLDR
This preliminary analysis of a phase II study suggests that high-dose rTNF alpha can be administered with acceptable toxicity by ILP with dopamine and hyperhydration, and combination of rT NF alpha, rIFN-gamma, and melphalan seems to achieve high efficacy with minimal toxicity, even after failure of prior therapy withMelphalan alone. Expand
...
1
2
3
4
...